Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P23467
UPID:
PTPRB_HUMAN
Alternative names:
Vascular endothelial protein tyrosine phosphatase
Alternative UPACC:
P23467; B7ZKS8; B7ZKT0; C9JX87; F5H3G6; Q14D85; Q3MIV7
Background:
The Receptor-type tyrosine-protein phosphatase beta, also known as Vascular endothelial protein tyrosine phosphatase, is pivotal in blood vessel remodeling and angiogenesis. It is not required for the initial formation of blood vessels but plays a crucial role in their maintenance and remodeling. This protein induces dephosphorylation of key endothelial markers, regulating angiopoietin-TIE2 signaling and controlling endothelial cell proliferation, which is essential for blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth.
Therapeutic significance:
Understanding the role of Receptor-type tyrosine-protein phosphatase beta could open doors to potential therapeutic strategies. Its essential function in maintaining endothelial cell contact integrity and the adhesive function of VE-cadherin in endothelial cells highlights its potential as a target for therapeutic intervention in vascular diseases.